Jean Abraham
 | The topic of this article may not meet Wikitia's general notability guideline. |
Jean Abraham | |
|---|---|
| Born | Kerala, India
December 1967 (age 58) |
| Alma mater | University of Liverpool
(MB ChB 1995) University of Cambridge (PhD 2011) St Hilda's Church of England High School |
| Known for | precision medicine, triple negative breast cancer, somatic evolution in cancer |
| Spouse(s) | Nick Blake.[1] |
| Scientific career | |
| Fields | Breast Cancer, Precision Medicine, |
| Institutions | University of Cambridge St Johns College, Cambridge |
| Thesis | Pharmacogenetics of breast cancer treatment (2011 Gonville and Caius College) |
| Doctoral advisor | Paul Pharoah |
| Other academic advisors | Carlos Caldas |
| Doctoral students | Karen Pinilla |
Jean Abraham (born 1967) is the Cambridge University Professor of Precision Medicine and Director of the Breast Programme in the Cancer Research UK Cambridge Centre.
Early life and education
Jean Abraham was born in Kerala, India, and moved to the United Kingdom when she was 2 years old. Her father was a GP in Liverpool.[2] She was state educated in a comprehensive school in the Sefton Park area of Liverpool. She did a first degree in Pharmacology at Liverpool University, before qualifying in medicine in 1995, also from Liverpool University. She completed her residency in internal medicine at Addenbrookes hospital with MRCP before specialising in medical oncology. She has two younger sisters, both doctors.
Research
Professor Abraham leads the Cambridge Precision Breast Cancer Unit which integrates routine whole genome/RNA sequencing service into a standard clinical service.
In 2023 the US Department of Defense Office of Naval Research awarded a $6.5 million grant for the further development of this program. The Synergia-Breast Cancer Platform will integrate data from multiple sources (pathology, genomics, radiomics, microbiome, translational science) to create a single point of access for research, including machine learning and artifical intelligence[3]
Professor Abraham is Chief Investigator of the Partner Trial[4] which showed that there was no benefit from adding olaparib to standard chemotherapy for patients with triple negative breast cancer if they did not have a BRCA1 or BRCA2 mutation.
Awards
- 2017 – Top 50 Female Movers and Shakers in UK BioHealth[5]
- 2022 – NIHR Team Research East of England Excellence Award[6]
References
- ↑ "Barristers of Farrars Chambers".
- ↑ "BMJ article". doi:10.1136/bmj.l776.
- ↑ Sammut, S. J.; Crispin-Ortuzar, M.; Chin, S. F.; Provenzano, E.; Bardwell, H. A.; Ma, W.; Cope, W.; Dariush, A.; Dawson, S. J.; Abraham, J. E.; Dunn, J.; Hiller, L.; Thomas, J.; Cameron, D. A.; Bartlett JMS; Hayward, L.; Pharoah, P. D.; Markowetz, F.; Rueda, O. M.; Earl, H. M.; Caldas, C. (2022). "Multi-omic machine learning predictor of breast cancer therapy response. Nature 2022". Nature. 601 (7894): 623–629. doi:10.1038/s41586-021-04278-5. PMC 8791834. PMID 34875674.
- ↑ Abraham, J. E.; et al. (2024). "The Partner trial of neoadjuvant Olaparib with chemotherapy in triple negative breast cancer. Nature 2024". Nature. 629 (8014): 1142–1148. doi:10.1038/s41586-024-07384-2.
- ↑ "Top Movers and Shakers" (PDF).
- ↑ "East of England Excellence Award". 19 December 2022.
External links
This article "Jean Abraham" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.